Altimmune (ALT) Operating Leases (2022 - 2026)

Altimmune (ALT) has 5 years of Operating Leases data on file, last reported at $1.1 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $1.1 million, down 19.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (down 19.75% YoY), and the FY2025 annual result was $1.1 million, down 18.33% from the prior year.
• Operating Leases declined to $1.1 million in Q1 2026 per ALT's latest filing, from $1.1 million in the prior quarter.
• Over five years, Operating Leases peaked at $1.5 million in Q2 2024 and troughed at $44000.0 in Q1 2024.
• A 5-year average of $1.0 million and a median of $1.2 million in 2025 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2023 and 2025: Operating Leases sank 73.96% in 2023, then jumped 2950.0% in 2025.
• A 5-year view of Operating Leases shows it stood at $672000.0 in 2022, then plunged by 73.96% to $175000.0 in 2023, then soared by 701.14% to $1.4 million in 2024, then slipped by 18.33% to $1.1 million in 2025, then declined by 5.94% to $1.1 million in 2026.
• Business Quant data shows ALT's Operating Leases at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $1.2 million in Q3 2025.